Expert Interview
A Second Look: Discussing the role of the PRC2/EZH2/EED pathway in prostate cancer
Ticker(s): ORIC, EPIX, PFEInstitution: Yale
- Professor of Medicine and Urology at Yale.
- Principal investigator or co-principal investigator on several SWOG clinical trials for genitourinary cancers.
- Authored more than 100 peer-reviewed articles on prostate and bladder cancer research
Roughly how many patients with prostate cancer do you currently manage?
Added By: c_adminCould you provide an overview of the PRC2/EZH2/EED pathway and its significance in prostate cancer?
What are your thoughts on the recent data presented by Pfizer regarding the EZH2 inhibitor PF-0821497 in combination with enzalutamide?
How do you interpret the confirmed PSA 50 response rate of 15% in the Pfizer study, and what implications does it have for future research?
What are the key considerations when evaluating the median progression-free survival (PFS) of 11.7 months in the context of small patient numbers?
Could you discuss the safety profile observed in the Pfizer study and how it compares to enzalutamide monotherapy?
What potential do you see for EZH2 inhibitors in earlier lines of therapy, such as hormone-sensitive prostate cancer?
How do you view the competitive landscape for EZH2 inhibitors, particularly with other emerging agents like those from Oric Pharmaceuticals?
What are the potential benefits and challenges of combining PRC2/EZH2 inhibitors with other androgen receptor inhibitors like apalutamide and darolutamide?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
